Lupin, Aurobindo Pharma Forced To Recall US Market Products
Lupin and Aurobindo recall products from US market due to USFDA alerts on manufacturing issues.
Two major pharmaceutical companies, Lupin and Aurobindo
Pharma, have taken action to withdraw specific products from the US market
following alerts from the US Food and Drug Administration (USFDA) regarding
manufacturing issues.
According to the most recent USFDA Enforcement Report, Lupin
Pharmaceuticals Inc., located in Baltimore, is recalling 3,552 bottles of
Cefixime for Oral Suspension because they do not meet the required standards
for uniform content. This particular batch was manufactured at their Mandideep
facility in Madhya Pradesh.
In the same way, Eugia US LLC, a subsidiary of Aurobindo Pharma based in New Jersey, is recalling 70,125 vials of Dexamethasone Sodium Phosphate injection and 15,500 single-dose vials of Eptifibatide injection because they did not meet the specified standards for impurities or degradation. These recalls were initiated on May 23 and May 22 respectively.
My international experience as a researcher in Taiwan for three years has equipped me with a global perspective, enabling me to create content that resonates with an international audience.
Plus dans Pharma News
Tous les articles →
Ab Science révise les calendriers d'essais après trois inspections GCP
Novo Nordisk signe un accord de 2,6 milliards $ avec Hengrui pour un GLP-1 oral
Discussion